02/13/2018
by Ken Wahl, Data Insights, Guidepoint Shire Plc’s (NYSE: SHPG) US hemophilia sales have faced much competition in recent years. In particular, their leading hemophilia A treatment Advate, an older, shorter-acting recombinant factor VIII, is facing many new US market…